Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

XNCR vs ALKS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
XNCR
Xencor, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$954M
5Y Perf.-57.0%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.89B
5Y Perf.+115.9%

XNCR vs ALKS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
XNCR logoXNCR
ALKS logoALKS
IndustryBiotechnologyBiotechnology
Market Cap$954M$5.89B
Revenue (TTM)$93M$1.56B
Net Income (TTM)$-172M$153M
Gross Margin94.4%65.4%
Operating Margin-144.7%12.3%
Forward P/E24.7x
Total Debt$188M$70M
Cash & Equiv.$54M$1.12B

XNCR vs ALKSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

XNCR
ALKS
StockMay 20May 26Return
Xencor, Inc. (XNCR)10043.0-57.0%
Alkermes plc (ALKS)100215.9+115.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: XNCR vs ALKS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Xencor, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
XNCR
Xencor, Inc.
The Growth Play

XNCR is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 13.7%, EPS growth 65.4%, 3Y rev CAGR -8.6%
  • 14.8% 10Y total return vs ALKS's -7.7%
  • 13.7% revenue growth vs ALKS's -5.2%
Best for: growth exposure and long-term compounding
ALKS
Alkermes plc
The Income Pick

ALKS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.06
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthXNCR logoXNCR13.7% revenue growth vs ALKS's -5.2%
Quality / MarginsALKS logoALKS9.8% margin vs XNCR's -185.7%
Stability / SafetyALKS logoALKSBeta 1.06 vs XNCR's 1.99, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)XNCR logoXNCR+53.8% vs ALKS's +16.3%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs XNCR's -20.5%, ROIC 18.9% vs -16.3%

XNCR vs ALKS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

XNCRXencor, Inc.
FY 2025
Royalty
63.9%$80M
Milestone
36.1%$45M
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M

XNCR vs ALKS — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGXNCR

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

ALKS is the larger business by revenue, generating $1.6B annually — 16.8x XNCR's $93M. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to XNCR's -185.7%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricXNCR logoXNCRXencor, Inc.ALKS logoALKSAlkermes plc
RevenueTrailing 12 months$93M$1.6B
EBITDAEarnings before interest/tax-$127M$212M
Net IncomeAfter-tax profit-$172M$153M
Free Cash FlowCash after capex-$189M$392M
Gross MarginGross profit ÷ Revenue+94.4%+65.4%
Operating MarginEBIT ÷ Revenue-144.7%+12.3%
Net MarginNet income ÷ Revenue-185.7%+9.8%
FCF MarginFCF ÷ Revenue-2.0%+25.1%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%+28.2%
EPS Growth (YoY)Latest quarter vs prior year-159.1%-4.1%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

XNCR leads this category, winning 2 of 3 comparable metrics.
MetricXNCR logoXNCRXencor, Inc.ALKS logoALKSAlkermes plc
Market CapShares × price$954M$5.9B
Enterprise ValueMkt cap + debt − cash$1.1B$4.8B
Trailing P/EPrice ÷ TTM EPS-10.49x24.70x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.20x
Price / SalesMarket cap ÷ Revenue7.60x3.99x
Price / BookPrice ÷ Book value/share1.52x3.28x
Price / FCFMarket cap ÷ FCF12.25x
XNCR leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 9 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-24 for XNCR. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to XNCR's 0.30x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs XNCR's 3/9, reflecting strong financial health.

MetricXNCR logoXNCRXencor, Inc.ALKS logoALKSAlkermes plc
ROE (TTM)Return on equity-23.7%+8.8%
ROA (TTM)Return on assets-20.5%+5.4%
ROICReturn on invested capital-16.3%+18.9%
ROCEReturn on capital employed-21.6%+14.2%
Piotroski ScoreFundamental quality 0–937
Debt / EquityFinancial leverage0.30x0.04x
Net DebtTotal debt minus cash$134M-$1.0B
Cash & Equiv.Liquid assets$54M$1.1B
Total DebtShort + long-term debt$188M$70M
Interest CoverageEBIT ÷ Interest expense-0.98x32.30x
ALKS leads this category, winning 9 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ALKS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,047 today (with dividends reinvested), compared to $3,275 for XNCR. Over the past 12 months, XNCR leads with a +53.8% total return vs ALKS's +16.3%. The 3-year compound annual growth rate (CAGR) favors ALKS at 4.5% vs XNCR's -21.9% — a key indicator of consistent wealth creation.

MetricXNCR logoXNCRXencor, Inc.ALKS logoALKSAlkermes plc
YTD ReturnYear-to-date-12.8%+25.0%
1-Year ReturnPast 12 months+53.8%+16.3%
3-Year ReturnCumulative with dividends-52.4%+14.3%
5-Year ReturnCumulative with dividends-67.2%+60.5%
10-Year ReturnCumulative with dividends+14.8%-7.7%
CAGR (3Y)Annualised 3-year return-21.9%+4.5%
ALKS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than XNCR's 1.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.5% from its 52-week high vs XNCR's 69.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricXNCR logoXNCRXencor, Inc.ALKS logoALKSAlkermes plc
Beta (5Y)Sensitivity to S&P 5001.99x1.06x
52-Week HighHighest price in past year$18.69$36.60
52-Week LowLowest price in past year$6.92$25.17
% of 52W HighCurrent price vs 52-week peak+69.6%+96.5%
RSI (14)Momentum oscillator 0–10053.466.6
Avg Volume (50D)Average daily shares traded861K2.3M
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates XNCR as "Buy" and ALKS as "Buy". Consensus price targets imply 148.5% upside for XNCR (target: $32) vs 24.6% for ALKS (target: $44).

MetricXNCR logoXNCRXencor, Inc.ALKS logoALKSAlkermes plc
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$32.33$44.00
# AnalystsCovering analysts2728
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.5%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XNCR leads in 1 (Valuation Metrics).

Best OverallAlkermes plc (ALKS)Leads 4 of 6 categories
Loading custom metrics...

XNCR vs ALKS: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is XNCR or ALKS a better buy right now?

For growth investors, Xencor, Inc.

(XNCR) is the stronger pick with 13. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 7x trailing P/E, making it the more compelling value choice. Analysts rate Xencor, Inc. (XNCR) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — XNCR or ALKS?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

5%, compared to -67. 2% for Xencor, Inc. (XNCR). Over 10 years, the gap is even starker: XNCR returned +14. 8% versus ALKS's -7. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — XNCR or ALKS?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus Xencor, Inc. 's 1. 99β — meaning XNCR is approximately 88% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 30% for Xencor, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — XNCR or ALKS?

By revenue growth (latest reported year), Xencor, Inc.

(XNCR) is pulling ahead at 13. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Xencor, Inc. grew EPS 65. 4% year-over-year, compared to -34. 1% for Alkermes plc. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — XNCR or ALKS?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -73. 2% for Xencor, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -141. 4% for XNCR. At the gross margin level — before operating expenses — XNCR leads at 91. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — XNCR or ALKS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is XNCR or ALKS better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). Xencor, Inc. (XNCR) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -7. 7%, XNCR: +14. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between XNCR and ALKS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

XNCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 56%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform XNCR and ALKS on the metrics below

Revenue Growth>
%
(XNCR: -100.0% · ALKS: 28.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.